Key regions: United States, Europe, Brazil, Japan, United Kingdom
Bronchodilator drugs are commonly used to treat respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). In Southern Africa, the market for these drugs is developing in response to various factors.
Customer preferences: Patients in Southern Africa are increasingly seeking out bronchodilator drugs as a means of managing their respiratory conditions. This is due in part to the high prevalence of asthma and COPD in the region, which has led to greater awareness of the benefits of these medications. Additionally, many patients prefer bronchodilator drugs over other treatment options due to their ease of use and relatively low cost.
Trends in the market: One trend that has emerged in the Southern African bronchodilator drugs market is the increasing availability of generic versions of these medications. This has led to greater competition among drug manufacturers, which has in turn driven down prices and made these drugs more accessible to patients. Another trend is the growing use of combination therapies, which combine bronchodilator drugs with other medications to provide more comprehensive treatment for respiratory conditions.
Local special circumstances: One factor that has contributed to the development of the bronchodilator drugs market in Southern Africa is the region's high burden of respiratory disease. This has led to greater demand for these medications, as well as increased investment in research and development by pharmaceutical companies. Additionally, the region's relatively low per capita income has made cost a major consideration for many patients, which has led to the emergence of a thriving market for generic versions of these drugs.
Underlying macroeconomic factors: The Southern African bronchodilator drugs market is influenced by a range of macroeconomic factors, including population growth, urbanization, and changing disease patterns. As the region's population continues to grow and become more urbanized, demand for these medications is likely to increase. Additionally, the increasing prevalence of respiratory disease in the region is likely to drive further growth in the market for bronchodilator drugs. However, factors such as regulatory changes and shifts in healthcare policy could also have an impact on the market in the coming years.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
